Fertility shield: goserelin injection may preserve ovarian function after stem cell transplant

NCT ID NCT07552493

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a single injection of goserelin, given just before a stem cell transplant, can help preserve ovarian function in women with blood cancers. The trial will enroll 64 women aged 14 to 50 and measure if their menstrual cycles return naturally within six months after the transplant. The goal is to reduce the risk of early menopause and infertility caused by the high-dose chemotherapy used in the transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
goserelin
What this could lead to
If it works, this could offer a way to protect fertility and ovarian function in women undergoing stem cell transplants for blood cancers.
What could go wrong
This is a small, early-stage trial with only 64 participants. The drug may not improve menstrual recovery, and there could be side effects from the hormone suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450000, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

  • The First People's Hospital of Yunnan Province

    Kunming, Yunnan, 650000, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.